Biopharmaceutical company eFFECTOR Therapeutics and Locust Walk Acquisition today announced they have entered into a definitive merger agreement that gives the combiend company a $419 million enterprise value.
Gross proceeds include $60 million from a committed PIPE and up to $175 million held in trust by the SPAC.
Pending regulatory and shareholder approvals, upon completion of the merger eFFECTOR Therapeutics is expected to list on the Nasdaq under EFTR. The deal is expected to close in the third quarter.
eFFector develops therapeutic drugs for the treatment of cancer. Read more.
